Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug [Seeking Alpha]
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: Seeking Alpha
The trial targeting a neurocondition called cerebral cavernous malformation (CCM) met the primary endpoint of safety and tolerability after 12 months of therapy, Recursion ( RXRX ) said. However, the company added that while data for MRI-based secondary efficacy endpoints were promising, it has yet to see improvements in either patient—or physician-reported outcomes at that time point. In July 2023, Recursion ( RXRX ) sparked a rally in AI-driven biopharma stocks after winning a $50M investment from Nvidia ( NVDA However, in the wake of the readout, Recursion ( RXRX ) shares plunged ~11% , marking its biggest intraday loss in over two months, albeit on below-average volumes, while Nvidia ( NVDA fell ~8% Exscientia ( EXAI ), another AI-based biotech that Recursion ( RXRX ) agreed to acquire last month, lost ~9% Other AI-based drug developers, Absci ( ABSI ), AbCellera Biologics ( ABCL ), and Tempus AI ( TEM ), were also in the red, while Schrödinger ( SDGR ) and BioSig Techn
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline [Seeking Alpha]Seeking Alpha
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery [Yahoo! Finance]Yahoo! Finance
- AI in Healthcare Market to Grow by USD 20.34 Billion (2024-2028), Driven by Healthcare Digitization, AI-Powered Report Highlights Market Transformation - TechnavioPR Newswire
- Recursion and Exscientia Shareholders Approve the Proposed Combination [Yahoo! Finance]Yahoo! Finance
- Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™PR Newswire
EXAI
Earnings
- 8/15/24 - Miss
EXAI
Sec Filings
- 11/20/24 - Form S-8
- 11/20/24 - Form S-8
- 11/20/24 - Form 6-K
- EXAI's page on the SEC website